Answer
Because cobimetinib excretion in human breast milk is unknown and risk to newborns/infants cannot be excluded, a decision should be made whether to discontinue breastfeeding or Cotellic therapy, considering the benefit of breastfeeding for the child and therapy for the woman.
Sources for this answer
- Cotellic 20 mg film-coated tabletsRoche Products Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 14Document updated
Sources checked